Leading the way to new and better cancer treatments

About Polaris

Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.
Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.

Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China.

Clinical Trials

Pegargiminase is in clinical development for numerous oncology indications.
Mesothelioma
Phase 3
Soft Tissue Sarcoma
Phase 2
Glioblastoma
Phase 1
Hepatic Cell Carcinoma
Phase 2/3
Acute Myeloid Leukemia
Phase 1

Development and Manufacturing Capabilities

Company News

Uncategorized

Polaris Group Has Entered Into An Agreement With The University Of California,Irvine(UCI) To Develop A Universal Influenza And Coronavirus Vaccine.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Read More
Uncategorized

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas

SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI‑PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas. The results were presented by Dr. Peter Szlosarek from Barts Cancer Center in the UK (abstract No.2589) at the American Society Clinical Oncology’s 2018 annual meeting.

Read More
Uncategorized

Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board

Read More
Uncategorized

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

SAN DIEGO, July 9, 2018 — Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.

Read More

Contact Us

Thank you for visiting. Please fill out the form with your specific details and submit it to us. We will contact you shortly. Thank you. *required.




    Enter Captcha Here :

    Scroll to Top